Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myeloma

Yuko Mishima; Yuko Shirouchi; Tomoko Takayama; Sayuri Minowa; Yuko Ishihara; Kei Hirano; Mitsuhito Hirano; Kikuaki Yoshida; Yukako Teramoto; Nobuhiko Yamauchi; Siew-Kee Low; Dai Maruyama

doi:10.3960/jslrt.24077

Short Communication

Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myeloma

Yuko Mishima , Yuko Shirouchi, Tomoko Takayama, Sayuri Minowa, Yuko Ishihara, Kei Hirano, Mitsuhito Hirano, Kikuaki Yoshida, Yukako Teramoto, Nobuhiko Yamauchi, Siew-Kee Low, Dai Maruyama

著者情報

Yuko Mishima 責任著者
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Division of Clinical Research, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan,
Yuko Shirouchi
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Tomoko Takayama
Division of Clinical Research, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan,
Sayuri Minowa
Division of Clinical Research, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan,
Yuko Ishihara
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Kei Hirano
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Mitsuhito Hirano
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Kikuaki Yoshida
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Yukako Teramoto
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Nobuhiko Yamauchi
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,
Siew-Kee Low
Liquid Biopsy Diagnosis Development Project, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan
Dai Maruyama
Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,

キーワード: multiple myeloma, somatic mutation, prognostic factor, NRAS

ジャーナルオープンアクセス

2025 年 65 巻 1 号 p. 72-76

DOI https://doi.org/10.3960/jslrt.24077

詳細

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）